NAGE Q3 2017 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$392M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+54.5% YoY

Gross Profit

$3M47.9% margin

Operating Income

-$3M-52.2% margin

Net Income

$2M35.1% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+44.2%

Cash Flow

Operating Cash Flow

-$475,000

Free Cash Flow

-$1M

Stock-Based Comp.

$491,000

Balance Sheet

Total Assets

$42M

Total Liabilities

$8M

Stockholders' Equity

$34M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+54.5%
Gross Profit	$3M	$2M	+56.5%
Operating Income	-$3M	-$924,162	-243.7%
Net Income	$2M	-$954,390	+323.9%